2-(tetrahydro-2H-pyran-4-ylamino)quinazoline-7-carboxylic acid | 1422188-30-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-(tetrahydro-2H-pyran-4-ylamino)quinazoline-7-carboxylic acid
• 英文别名: 2-(Oxan-4-ylamino)quinazoline-7-carboxylic acid；2-(oxan-4-ylamino)quinazoline-7-carboxylic acid
• CAS: 1422188-30-4
• 化学式: C₁₄H₁₅N₃O₃
• 分子量: 273.291
• InChiKey: WIVJYUYFVAZMMS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  84.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(tetrahydro-2H-pyran-4-ylamino)quinazoline-7-carboxylic acid 、 tert-butyl 3-(amino(3-chloro-4-fluorophenyl)methyl)-3-fluoropyrrolidine-1-carboxylate 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 作用下， 以 N,N-二甲基甲酰胺 、 二氯甲烷 为溶剂， 反应 18.0h， 以54.3%的产率得到N-[(3-chloro-4-fluorophenyl)-(3-fluoropyrrolidin-3-yl)methyl]-2-(oxan-4-ylamino)quinazoline-7-carboxamide
  参考文献：
  名称：

  [EN] QUINAZOLINE COMPOUNDS AS SERINE/THREONINE KINASE INHIBITORS
  [FR] COMPOSÉS DE QUINAZOLINE UTILES EN TANT QU'INHIBITEURS DE LA SÉRINE/THRÉONINE KINASE

  摘要：

  具有化学式（I）的化合物，在该式中R1、R2、R3和Ar的定义为ERK激酶的抑制剂。还披露了用于治疗过度增殖性疾病的组合物和方法。

  公开号：

  WO2013020062A1

文献信息

• QUINAZOLINE COMPOUNDS AS SERINE/THREONINE KINASE INHIBITORS
  申请人：Blake James F.

  公开号：US20150087664A1

  公开（公告）日：2015-03-26

  Compounds having the formula (I) wherein R 1 , R 2 , R 3 and Ar as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.

  具有公式（I）的化合物，其中R1，R2，R3和Ar如此定义的化合物是ERK激酶的抑制剂。本文还披露了治疗过度增殖性疾病的组合物和方法。
• USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER
  申请人：Del Mar Pharmaceuticals

  公开号：EP3125920A2

  公开（公告）日：2017-02-08
• EP3125920B1
  申请人：——

  公开号：EP3125920B1

  公开（公告）日：2020-12-23
• COMBINATION OF ANALOGS OR DERIVATIVES OF DIANHYDROGALACTITOL WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT CANCER
  申请人：Delmar Pharmaceuticals, Inc.

  公开号：EP3294284A1

  公开（公告）日：2018-03-21
• USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES
  申请人：Del Mar Pharmaceuticals

  公开号：US20160008316A1

  公开（公告）日：2016-01-14

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N 7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or super-additive effects.